1. |
兰锡纯, 冯卓荣. 心脏血管外科[M]. 第2版. 北京:人民卫生出版社, 2002:1234-1241, 1406-1418.
|
2. |
王嘉桔, 赵文光, 孙思翘, 等. 血栓闭塞性脉管炎治疗方法的演变和现状(百年回顾之三)[J/OL]. 中国血管外科杂志(电子版), 2011, 3(2):80-83, 87.
|
3. |
黎建华, 汤秀芬. 肾上腺皮质激素治疗血栓闭塞性脉管炎急性期的临床观察[J]. 当代医学, 2009, 15(16):97-98.
|
4. |
Qi R, Ozaki Y, Satoh K, et al. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin[J]. Thromb Res, 1996, 81(1):43-54.
|
5. |
Rashid M, Manivet P, Nishio H, et al. Identification of the bindingsites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling[J]. Life Sci, 2003, 73(2):193-207.
|
6. |
HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease[J]. Clin Cardiol, 2002, 25(1):28-32.
|
7. |
Jeflrey W, Olin Do. Thromboangiitis Obliterans (BuergersDisease)//Rutherford RB. Vascular Surgery[M]. 6th ed,Elsevier, Inc. 2005:404-416.
|
8. |
Chen YW, Iwai T, Umeda M, et al. Elevated IgG titers to periodontal pathogens related to Buerger disease[J]. Int J Cardiol, 2007, 122(1):79-81.
|
9. |
Sharma SK, Zahradka P, Chapman D, et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate[J]. J Pharmacol Exp Ther, 1999, 290(3):1475-1481.
|
10. |
Nakamura K, Kariyazono H, Masuda H, et al. Effects ofsarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans[J]. Blood Coagul Fibrinolysis, 2001, 12(5):391-397.
|
11. |
霍勇, 孟磊, 温绍君, 等. 抗血小板药物在动脉血栓栓塞性疾病中的合理应用[J]. 中华内科杂志, 2006, 45(4):347-348.
|
12. |
Satomura K, Takase B, Hamabe A, et al. Sarpogrelate, a specific.
|
13. |
Mikawa K, Akamatsu H, Nishina K, et al. The effects ofsarpogrelate on superoxide production by human neutrophils[J]. Reg Anesth Pain Med, 2000, 25(2):181-186.
|
14. |
Yamashita T, Kitamori K, Hashimoto M, et al. Conjunctiveeffects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in differentlaser-induced thrombosis models[J]. Haemostasis, 2000, 30(6):321-332.
|
15. |
Kandabashi T, Shimokawa H, Mukai Y, et al. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotichuman arteries[J]. Arterioscler Thromb Vasc Biol, 2002, 22(2):243-248.
|
16. |
Ogawa T, Ogura T, Hirata A, et al. Sarpogrelate hydrochloride therapy for Raynaud’s phenomenon in patients with systemic sclerosis[J]. Interna J Rheum Dis, 2008, 11(suppl):P30-04, A483.
|